Skip to main content
GMED
NYSE Industrial Applications And Services

Globus Medical Cuts 2026 Revenue Guidance to $3.09B, Adds $500M to Buyback

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$80.31
Mkt Cap
$10.934B
52W Low
$60.255
52W High
$101.398
52W Position info
33% above low
Off High info
21% below high
Rel. Volume info
2.7× avg
Market data snapshot near publication time

GMED sits 33% above its 52-week low of $60.255 on elevated volume (2.7× avg).

Summary

Globus Medical trimmed full-year 2026 revenue guidance to $3.09 billion from $3.18-$3.22 billion while reaffirming EPS guidance. Its board also added $500 million to the share repurchase program, leaving about $611 million available.


Key Events · Earnings and Guidance · GMED

  • 2026 Revenue Guidance Cut to $3.09B

    Full-year 2026 revenue guidance was lowered to $3.09 billion from the previous range of $3.18 billion to $3.22 billion, still representing 5.1% growth over fiscal 2025.

  • Q3 Sales Slip 0.7% to $763.7M

    Worldwide net sales were $763.7 million, down 0.7% as reported and 0.5% in constant currency. Base business excluding Nevro rose 3.0% to $690.0 million, while international fell 5.7%.

  • EPS Guidance Reaffirmed at $4.95-$5.05

    Non-GAAP fully diluted EPS guidance for fiscal 2026 was reaffirmed at $4.95 to $5.05, representing 24.4% to 26.9% growth over fiscal 2025; Q3 non-GAAP diluted EPS was $1.23, up 4.4%.

  • $500M Added to Share Repurchase Program

    On November 2, 2026 the board authorized an additional $500.0 million of Class A common stock repurchases, leaving approximately $611.0 million available; the program has no expiration date.


Analysis · GMED · Industrial Applications And Services

The headline move is a revenue guidance cut to $3.09 billion from a prior $3.18-$3.22 billion range, even as non-GAAP EPS guidance of $4.95-$5.05 was reaffirmed. Lower sales with a held profit line implies margin expansion rather than volume growth. Third-quarter sales of $763.7 million fell 0.7% year over year, with U.S. Spine up only 2% against tough comparables and international down 5.7%. Offsetting the softer top line, the board added $500 million to the buyback, leaving roughly $611 million available, and the company generated record quarterly operating and free cash flow of $265.2 million and $224.8 million respectively. That tension — a trimmed revenue outlook paired with a bigger repurchase authorization — is the story: management is leaning on cash return while the core spine business digests a strong prior-year quarter.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GMED was trading at $80.31 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $10.9B. The 52-week trading range was $60.26 to $101.40. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GMED - Latest Insights

GMED
Nov 05, 2026, 5:08 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $77.60
Real-time Price: $66.89 info
Change: -$10.71 (-14%) info
Market Cap: $8.861B info
GMED
Nov 05, 2026, 4:02 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $81.52
Real-time Price: $66.89 info
Change: -$14.63 (-18%) info
Market Cap: $8.861B info
GMED
Nov 03, 2026, 4:02 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $79.58
Real-time Price: $66.89 info
Change: -$12.69 (-16%) info
Market Cap: $8.861B info
GMED
Aug 26, 2026, 5:57 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $82.96
Real-time Price: $66.89 info
Change: -$16.07 (-19%) info
Market Cap: $8.861B info
GMED
Aug 06, 2026, 4:19 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $84.00
Real-time Price: $66.89 info
Change: -$17.11 (-20%) info
Market Cap: $8.861B info